MX369567B - ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. - Google Patents

ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.

Info

Publication number
MX369567B
MX369567B MX2018004348A MX2018004348A MX369567B MX 369567 B MX369567 B MX 369567B MX 2018004348 A MX2018004348 A MX 2018004348A MX 2018004348 A MX2018004348 A MX 2018004348A MX 369567 B MX369567 B MX 369567B
Authority
MX
Mexico
Prior art keywords
roryt
modulators
syndrome
disorder
disease
Prior art date
Application number
MX2018004348A
Other languages
English (en)
Spanish (es)
Inventor
Steven Goldberg
Gerald Kleymann
Olaf Kinzel
Gege Christian
Anne M Fourie
Hariharan Venkatesan
Steeneck Christoph
Hoffmann Thomas
Xiaohua Xue
Tanis Virginia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54754732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369567(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX369567B publication Critical patent/MX369567B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018004348A 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT. MX369567B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072563P 2014-10-30 2014-10-30
PCT/US2015/058193 WO2016069974A1 (en) 2014-10-30 2015-10-30 TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt

Publications (1)

Publication Number Publication Date
MX369567B true MX369567B (es) 2019-11-12

Family

ID=54754732

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004348A MX369567B (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.
MX2017005689A MX367912B (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017005689A MX367912B (es) 2014-10-30 2015-10-30 ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.

Country Status (40)

Country Link
US (2) US9850236B2 (enExample)
EP (2) EP3212643B1 (enExample)
JP (3) JP6998204B2 (enExample)
KR (2) KR20170078750A (enExample)
CN (3) CN107108599A (enExample)
AR (2) AR102480A1 (enExample)
AU (2) AU2015339087B2 (enExample)
BR (2) BR112017008816A2 (enExample)
CA (1) CA2965512C (enExample)
CL (3) CL2017001042A1 (enExample)
CO (1) CO2017005014A2 (enExample)
CR (2) CR20170166A (enExample)
CY (1) CY1121716T1 (enExample)
DK (1) DK3212643T3 (enExample)
EA (2) EA033699B1 (enExample)
EC (1) ECSP17033054A (enExample)
ES (2) ES2858503T3 (enExample)
GT (1) GT201700090A (enExample)
HR (1) HRP20190900T1 (enExample)
HU (1) HUE043624T2 (enExample)
IL (2) IL251865A0 (enExample)
JO (2) JOP20200117A1 (enExample)
LT (1) LT3212643T (enExample)
MA (1) MA40873B1 (enExample)
ME (1) ME03426B (enExample)
MX (2) MX369567B (enExample)
PE (2) PE20171649A1 (enExample)
PH (2) PH12017500800B1 (enExample)
PL (1) PL3212643T3 (enExample)
PT (1) PT3212643T (enExample)
RS (1) RS58613B1 (enExample)
SG (2) SG10201805355YA (enExample)
SI (1) SI3212643T1 (enExample)
SM (1) SMT201900290T1 (enExample)
SV (1) SV2017005429A (enExample)
TR (1) TR201907763T4 (enExample)
TW (2) TWI667230B (enExample)
UY (2) UY36377A (enExample)
WO (1) WO2016069974A1 (enExample)
ZA (3) ZA201703679B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) * 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
WO2019177996A1 (en) * 2018-03-12 2019-09-19 Escalier Biosciences B.V. Bicyclic ror-gamma modulators
CN112118841A (zh) 2018-03-12 2020-12-22 爱思凯利尔生物科学私人有限责任公司 螺环ROR-γ调节剂
ES2928246T3 (es) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
US10975037B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of RORγt
JP2021527660A (ja) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
CN119528866B (zh) * 2024-11-28 2025-10-17 河南农业大学 一种含双三氟甲基的香豆素叔醇类化合物及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
EP1432690A2 (en) 2001-04-16 2004-06-30 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
HRP20040098B1 (en) 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
AR045651A1 (es) * 2003-09-19 2005-11-02 Solvay Pharm Bv Derivados de tiazol como moduladores del receptor de cannabinoide
WO2006124687A1 (en) 2005-05-12 2006-11-23 University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
EP1983980A4 (en) 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
BRPI0916218B1 (pt) 2008-07-17 2018-11-27 Bayer Cropscience Ag compostos heterocíclicos como composições praguicidas
US8377962B2 (en) * 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
US9492439B2 (en) 2010-03-11 2016-11-15 New York University Amido compounds as RORγt modulators and uses thereof
WO2011112264A1 (en) 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012074547A2 (en) 2010-11-29 2012-06-07 New York University STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
JP5981350B2 (ja) 2010-12-28 2016-08-31 ライオン株式会社 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
WO2013018695A1 (ja) 2011-07-29 2013-02-07 武田薬品工業株式会社 複素環化合物
MX2014002810A (es) 2011-09-09 2014-09-08 Univ New York Compuestos amido como moduladores del receptor nuclear huérfanoyt y usos de los mismos.
GB201116641D0 (en) * 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
CA2856946C (en) 2011-12-02 2016-08-02 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
KR101742954B1 (ko) * 2012-05-31 2017-06-02 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2909193B1 (en) * 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenyl linked quinolinyl modulators of ror-gamma-t
WO2014093191A1 (en) * 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
CN105308037B (zh) 2013-06-04 2017-09-19 阿克图拉姆生命科学股份公司 三唑化合物及其作为γ分泌酶调节剂的用途
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
EP3044219A1 (en) 2013-09-09 2016-07-20 Bristol-Myers Squibb Company Rorgamma modulators
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
EP3046906B1 (en) 2013-09-20 2017-08-16 Bristol-Myers Squibb Company Ror gamma modulators
CN105636952A (zh) * 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
AU2014334619A1 (en) * 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
UA117941C2 (uk) 2013-12-05 2018-10-25 Лід Фарма Холдінг Б.В. МОДУЛЯТОРИ ROR-ГAMMA (RORγ)
CA2936116A1 (en) 2014-01-06 2015-07-09 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
CN106061956B (zh) 2014-01-06 2021-03-12 百时美施贵宝公司 作为RORγ调节剂的杂环砜
EP3092216B1 (en) 2014-01-06 2018-12-12 Bristol-Myers Squibb Company Carbocyclic sulfone ror gamma modulators
US9708253B2 (en) 2014-01-06 2017-07-18 Bristol-Myers Squibb Company Cyclohexyl sulfone RORγ modulators
EP3122721A4 (en) 2014-03-27 2018-01-10 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
RS58250B1 (sr) 2014-10-30 2019-03-29 Janssen Pharmaceutica Nv Tiazoli kao modulatori roryt
SMT201900706T1 (it) 2014-10-30 2020-01-14 Janssen Pharmaceutica Nv Tiazoli sostituiti con ammide come modulatori di rorgammat

Also Published As

Publication number Publication date
MA40873B1 (fr) 2019-07-31
HUE043624T2 (hu) 2019-08-28
UY36377A (es) 2016-04-29
CR20170542A (es) 2018-02-20
US20160122336A1 (en) 2016-05-05
EA201891562A2 (ru) 2018-12-28
PE20171649A1 (es) 2017-11-13
MX367912B (es) 2019-09-11
BR112017008816A2 (pt) 2017-12-19
PH12017500800A1 (en) 2017-10-02
PH12017500800B1 (en) 2017-10-02
CN107108599A (zh) 2017-08-29
EA201790942A1 (ru) 2017-09-29
CY1121716T1 (el) 2020-07-31
AU2019200228A1 (en) 2019-01-31
EA201891562A3 (ru) 2019-04-30
AU2015339087B2 (en) 2020-01-23
RS58613B1 (sr) 2019-05-31
CL2017001042A1 (es) 2017-12-01
HK1258212A1 (en) 2019-11-08
ZA201703679B (en) 2019-06-26
TW201927759A (zh) 2019-07-16
ES2858503T3 (es) 2021-09-30
LT3212643T (lt) 2019-06-10
SI3212643T1 (sl) 2019-04-30
PE20180250A1 (es) 2018-02-02
EP3212643A1 (en) 2017-09-06
SV2017005429A (es) 2017-10-17
DK3212643T3 (da) 2019-05-13
TW201629027A (zh) 2016-08-16
SG10201805355YA (en) 2018-07-30
JP2018500287A (ja) 2018-01-11
TR201907763T4 (tr) 2019-06-21
CL2019001514A1 (es) 2019-10-04
KR20170127580A (ko) 2017-11-21
GT201700090A (es) 2019-08-08
EP3354651B1 (en) 2021-01-06
AR110155A2 (es) 2019-02-27
ME03426B (me) 2020-01-20
TWI705057B (zh) 2020-09-21
CN107827841A (zh) 2018-03-23
CR20170166A (es) 2017-08-22
EP3212643B1 (en) 2019-03-20
JP6623270B2 (ja) 2019-12-18
AU2015339087A1 (en) 2017-05-11
ECSP17033054A (es) 2018-01-31
MA40873A (fr) 2017-09-05
UY37517A (es) 2018-01-31
SG11201703323PA (en) 2017-05-30
ZA201805860B (en) 2019-11-27
JP2019059728A (ja) 2019-04-18
EA035998B1 (ru) 2020-09-10
ZA201805861B (en) 2019-11-27
CA2965512A1 (en) 2016-05-06
CL2018000436A1 (es) 2018-07-06
CO2017005014A2 (es) 2017-08-31
AR102480A1 (es) 2017-03-01
PH12017502105A1 (en) 2019-11-25
JP2020180129A (ja) 2020-11-05
IL251865A0 (en) 2017-06-29
JP6998204B2 (ja) 2022-02-04
CN112979630A (zh) 2021-06-18
CA2965512C (en) 2020-03-10
TWI667230B (zh) 2019-08-01
SMT201900290T1 (it) 2019-07-11
WO2016069974A1 (en) 2016-05-06
HRP20190900T1 (hr) 2019-07-12
EA033699B1 (ru) 2019-11-18
JO3571B1 (ar) 2020-07-05
AU2019200228B2 (en) 2020-04-16
IL255648B (en) 2020-06-30
MX2017005689A (es) 2018-02-19
US9850236B2 (en) 2017-12-26
BR122017023050A2 (pt) 2019-09-10
US10150762B2 (en) 2018-12-11
EP3354651A1 (en) 2018-08-01
ES2724556T3 (es) 2019-09-12
PL3212643T3 (pl) 2019-08-30
KR20170078750A (ko) 2017-07-07
US20170327492A1 (en) 2017-11-16
JOP20200117A1 (ar) 2017-06-16
IL255648A (en) 2018-01-31
PT3212643T (pt) 2019-06-17

Similar Documents

Publication Publication Date Title
PH12017500800A1 (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
MX358508B (es) Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
MX2018013143A (es) 6-aminopiridin-3-il tiazoles como moduladores de ror?t.
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
EP4219718A3 (en) Compositions and methods for modulating complement factor b expression
MX2018003472A (es) Moduladores de la expresion de kras.
HK1213250A1 (zh) RORγT的雜芳基連接的喹啉基調節劑
JOP20210050A1 (ar) معدلات تعبير pnpla3
TR201820513T4 (tr) Roryt modülatörleri olarak tiazoller.
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
WO2015057200A8 (en) Heteroaryl linked quinolinyl modulators of rorϒt
BR112016008257A2 (pt) moduladores de roryt de álcool quinolínico secundário
BR112016008183A2 (pt) Moduladores de ror-gama-t de quinolinila ligados à fenila